Death, CardiacMORCOR-TURKNCT05296694
Mortality Predictors in Coronary Care in Turkey
An observational study of Death, Cardiac, run by Afyonkarahisar Health Sciences University at 2 sites in Turkey (Türkiye).
Trial summary
This study was undertaken to investigate and document the mortality rates and predictors in coronary care unit (CCU) patients in Turkey. It is designed to be a multicenter, observational, cross-sectional, and descriptive study. It will be conducted in 50 centers in 12 regions of Turkey. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Death, Cardiac
- How many people
- 2,560 participants
- Where
- 2 sitesTurkey (Türkiye)
- Study dates
- 1 Sep 2022to 15 Oct 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: All patients (age≥18) admitted to the coronary intensive care unit for cardiovascular reasons in all centers participating in the study between the dates specified.
Who may be able to join
- 18 years of age or older
- hospitalized with cardiovascular diseases
- individuals (or relatives for unconscious patients) who gave written informed consent
Who cannot join
- younger than 18 years of age
- rejecting to sign an informed consent
- hospitalized to CCU by other departments with noncardiac indications
- patients with active severe noncardiac chronic disease (chronic obstructive pulmonary disease, systemic diseases, and malignancy)
- no vital signs despite adequate cardiopulmonary resuscitation during hospitalization
- rejected to stay in CCU and discharged with his/her own request
Trial locations and contacts
2 sites in 1 country.
Turkey (Türkiye)2 sites
Afyonkarahisar Health Sciences University
Afyonkarahisar, 03200
Kutahya Evliya Celebi Research and Training Hospital
Kütahya, 43040
About this study
Official title: Predictors of In-hospital MORtality in CORonary Care Patients in TURKey
This study was undertaken to investigate and document the mortality rates and predictors in coronary care unit (CCU) patients in Turkey.
It is designed to be a multicenter, observational, cross-sectional, and descriptive study. It will be conducted in 50 centers in 12 regions of Turkey. The study does not include any interventional or treatment procedures.
At the end of the study, clinicians will have up-to-date information about predictors of mortality in CCU patients.
Read the detailed description
The MORCOR-TURK study will be conducted as a nationwide registry in 50 tertiary cardiology centers selected from each EuroStat NUTS region in Turkey according to their population sample weight, prioritizing the volume of hospitals in each region. All consecutive patients admitted to the coronary care units (CCU) will be prospectively admitted during a predefined period of 1 month. The study will be conducted by cardiologists in hospitals who regularly treat cardiac patients. Led by the Cardiology Department of Kutahya Evliya Celebi Research and Training Hospital, 50 centers will be included in the study.
There has not been any large-scale epidemiological study on coronary care patients in Turkey recently. Therefore, up-to-date information in this group of patients is lacking. In particular, significant reductions in mortality and morbidity are expected, thanks to improved medical and interventional facilities. In the light of current data, the investigators designed a large-scale study to document mortality rates and predictors in CCU patients.
In this study, the investigators will include consecutive patients admitted to CCU with cardiovascular indications in all participating centers. Patients will be followed and treated by experienced cardiologists and no further experimental intervention will be planned. In the first part of the study, the investigators will record in-hospital mortality rates and try to identify the best predictors. In the second part of the MORCOR-TURK trial which will have a cohort design, the investigators will follow the successfully discharged patients for 1 year. At the end of the follow-up, investigators will assess the risk factors and predictors of cardiovascular events as secondary endpoints.
- Conditions
- Death, Cardiac
- Keywords
- Coronary Care Unit, Mortality, Predictors
- Medical subject headings
- Death
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Coronary Care Patients | All patients admitted to coronary care unit with cardiovascular diseases. |
What is being measured
The primary outcome is the main question the study is designed to answer.
All cause mortality
All types of mortality in-hospital follow up
Measured: In-hospital (up to two-weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2022
- Study start1 Sep 2022
- Primary completion1 Oct 2022
- Study completion15 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Death, CardiacStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 2,560 participants (actual)
Sponsor and investigators
- Lead sponsor
- Afyonkarahisar Health Sciences University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, İbrahim Ersoy, MD, Afyonkarahisar Health Sciences University
- Investigators
- Fatih Kahraman, MD, Study director, Kutahya Health Sciences University Evliya Celebi Research and Training Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05296694
- Sponsor's protocol ID
- 3450
- Acronym
- MORCOR-TURK
- Status last verified
- Jan 2023
- First submitted
- 8 Mar 2022
- Last updated
- 1 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Ratcliffe JA, Wilson E, Islam S, Platsman Z, Leou K, Williams G, Lucido D, Moustakakis E, Rachko M, Bergmann SR. Mortality in the coronary care unit. Coron Artery Dis. 2014 Jan;25(1):60-5. doi: 10.1097/MCA.0000000000000043.
PubMed 24121428Filizcan U, Kurc E, Cetemen S, Soylu O, Aydogan H, Bayserke O, Yilmaz M, Uyarel H, Ergelen M, Orhan G, Ugurlucan M, Eren E, Yekeler I. Mortality predictors in ST-elevated myocardial infarction patients undergoing coronary artery bypass grafting. Angiology. 2011 Jan;62(1):68-73. doi: 10.1177/0003319710369103. Epub 2010 May 12.
PubMed 20462895Hayiroglu MI, Keskin M, Uzun AO, Yildirim DI, Kaya A, Cinier G, Bozbeyoglu E, Yildirimturk O, Kozan O, Pehlivanoglu S. Predictors of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Complicated With Cardiogenic Shock. Heart Lung Circ. 2019 Feb;28(2):237-244. doi: 10.1016/j.hlc.2017.10.023. Epub 2017 Nov 14.
PubMed 29191504Campanile A, Castellani C, Santucci A, Annunziata R, Tutarini C, Reccia MR, Del Pinto M, Verdecchia P, Cavallini C. Predictors of in-hospital and long-term mortality in unselected patients admitted to a modern coronary care unit. J Cardiovasc Med (Hagerstown). 2019 May;20(5):327-334. doi: 10.2459/JCM.0000000000000785.
PubMed 30865139Taylan G, Kaya C, Ozbek M, Kurt F, Kacmaz Y, Akkaya F, Kahraman F, Yilmaz AS. Short-Term Prognosis of Elderly Patients Admitted to the Coronary Care Unit: A Subgroup Analysis of the MORCOR-TURK (Mortality and Morbidity in Coronary Care Units in Turkiye) Trial. Turk Kardiyol Dern Ars. 2024 Sep;52(6):411-419. doi: 10.5543/tkda.2024.51282.
PubMed 39225647Kahraman F, Ersoy I, Yilmaz AS, Atici A, Tekin AM, Acar B, Kaya C, Kara F, Kurt F, Avci Demir F, Cerik IB, Yilmaz I, Adali MK, Yeni M, Tascanov MB, Yenercag M, Sahin M, Duz R, Gulasti S, Omur SE, Topuz S, Hidayet S, Kacmaz Y, Aygul N. Rationale, Design, and Methodology of the MORCOR-TURK Trial: Predictors of In-hospital MORtality in CORonary Care Patients in Turkey. Anatol J Cardiol. 2023 May;27(5):258-265. doi: 10.14744/AnatolJCardiol.2022.2824.
PubMed 37119186
Study at a glance
From the registry record, last updated by the sponsor on 1 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predictors of In-hospital MORtality in CORonary Care Patients in TURKey
- ClinicalTrials.gov ID
- NCT05296694
- Acronym / sponsor ID
- MORCOR-TURK / 3450
- Conditions
- Death, Cardiac
- Keywords
- Coronary Care Unit, Mortality, Predictors
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 2,560 participants (actual)
- Lead sponsor
- Afyonkarahisar Health Sciences UniversityUniversity, hospital or other
- Study start
- 1 Sep 2022 (actual)
- Primary completion
- 1 Oct 2022 (actual)
- Study completion
- 15 Oct 2022 (actual)
- First posted
- 25 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study was undertaken to investigate and document the mortality rates and predictors in coronary care unit (CCU) patients in Turkey.
It is designed to be a multicenter, observational, cross-sectional, and descriptive study. It will be conducted in 50 centers in 12 regions of Turkey. The study does not include any interventional or treatment procedures.
At the end of the study, clinicians will have up-to-date information about predictors of mortality in CCU patients.
Detailed description
The MORCOR-TURK study will be conducted as a nationwide registry in 50 tertiary cardiology centers selected from each EuroStat NUTS region in Turkey according to their population sample weight, prioritizing the volume of hospitals in each region. All consecutive patients admitted to the coronary care units (CCU) will be prospectively admitted during a predefined period of 1 month. The study will be conducted by cardiologists in hospitals who regularly treat cardiac patients. Led by the Cardiology Department of Kutahya Evliya Celebi Research and Training Hospital, 50 centers will be included in the study.
There has not been any large-scale epidemiological study on coronary care patients in Turkey recently. Therefore, up-to-date information in this group of patients is lacking. In particular, significant reductions in mortality and morbidity are expected, thanks to improved medical and interventional facilities. In the light of current data, the investigators designed a large-scale study to document mortality rates and predictors in CCU patients.
In this study, the investigators will include consecutive patients admitted to CCU with cardiovascular indications in all participating centers. Patients will be followed and treated by experienced cardiologists and no further experimental intervention will be planned. In the first part of the study, the investigators will record in-hospital mortality rates and try to identify the best predictors. In the second part of the MORCOR-TURK trial which will have a cohort design, the investigators will follow the successfully discharged patients for 1 year. At the end of the follow-up, investigators will assess the risk factors and predictors of cardiovascular events as secondary endpoints.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Coronary Care Patients | – | –All patients admitted to coronary care unit with cardiovascular diseases. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- All patients (age≥18) admitted to the coronary intensive care unit for cardiovascular reasons in all centers participating in the study between the dates specified.
Key inclusion criteria (3 listed)
- 18 years of age or older
- hospitalized with cardiovascular diseases
- individuals (or relatives for unconscious patients) who gave written informed consent
Key exclusion criteria (6 listed)
- younger than 18 years of age
- rejecting to sign an informed consent
- hospitalized to CCU by other departments with noncardiac indications
- patients with active severe noncardiac chronic disease (chronic obstructive pulmonary disease, systemic diseases, and malignancy)
- no vital signs despite adequate cardiopulmonary resuscitation during hospitalization
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
All cause mortality
Time frame: In-hospital (up to two-weeks)
All types of mortality in-hospital follow up
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Feb 2023.
- Background: PubMed 24121428Ratcliffe JA, Wilson E, Islam S, Platsman Z, Leou K, Williams G, Lucido D, Moustakakis E, Rachko M, Bergmann SR. Mortality in the coronary care unit. Coron Artery Dis. 2014 Jan;25(1):60-5. doi: 10.1097/MCA.0000000000000043.
- Background: PubMed 20462895Filizcan U, Kurc E, Cetemen S, Soylu O, Aydogan H, Bayserke O, Yilmaz M, Uyarel H, Ergelen M, Orhan G, Ugurlucan M, Eren E, Yekeler I. Mortality predictors in ST-elevated myocardial infarction patients undergoing coronary artery bypass grafting. Angiology. 2011 Jan;62(1):68-73. doi: 10.1177/0003319710369103. Epub 2010 May 12.
- Background: PubMed 29191504Hayiroglu MI, Keskin M, Uzun AO, Yildirim DI, Kaya A, Cinier G, Bozbeyoglu E, Yildirimturk O, Kozan O, Pehlivanoglu S. Predictors of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Complicated With Cardiogenic Shock. Heart Lung Circ. 2019 Feb;28(2):237-244. doi: 10.1016/j.hlc.2017.10.023. Epub 2017 Nov 14.
- Background: PubMed 30865139Campanile A, Castellani C, Santucci A, Annunziata R, Tutarini C, Reccia MR, Del Pinto M, Verdecchia P, Cavallini C. Predictors of in-hospital and long-term mortality in unselected patients admitted to a modern coronary care unit. J Cardiovasc Med (Hagerstown). 2019 May;20(5):327-334. doi: 10.2459/JCM.0000000000000785.
- Derived from this study: PubMed 39225647Taylan G, Kaya C, Ozbek M, Kurt F, Kacmaz Y, Akkaya F, Kahraman F, Yilmaz AS. Short-Term Prognosis of Elderly Patients Admitted to the Coronary Care Unit: A Subgroup Analysis of the MORCOR-TURK (Mortality and Morbidity in Coronary Care Units in Turkiye) Trial. Turk Kardiyol Dern Ars. 2024 Sep;52(6):411-419. doi: 10.5543/tkda.2024.51282.
- Derived from this study: PubMed 37119186Kahraman F, Ersoy I, Yilmaz AS, Atici A, Tekin AM, Acar B, Kaya C, Kara F, Kurt F, Avci Demir F, Cerik IB, Yilmaz I, Adali MK, Yeni M, Tascanov MB, Yenercag M, Sahin M, Duz R, Gulasti S, Omur SE, Topuz S, Hidayet S, Kacmaz Y, Aygul N. Rationale, Design, and Methodology of the MORCOR-TURK Trial: Predictors of In-hospital MORtality in CORonary Care Patients in Turkey. Anatol J Cardiol. 2023 May;27(5):258-265. doi: 10.14744/AnatolJCardiol.2022.2824.
Related trials for Death, Cardiac
RecruitingObservational study
Genetic Markers of Cardiovascular Disease in Epilepsy
Epilepsy, Seizures
RecruitingObservational study
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
Chronic Lymphocytic Leukemia (CLL), Waldenstr(SqrRoot)(Delta)m s Macroglobulinemia
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
Not yet recruitingPhase 3
Cilostazol for Prevention of Recurrent Stroke Trial
Stroke Recurrence, Myocardial Infarction
Recruiting
Study of the Link Between Structural Alterations in the Hypothalamus and Cardiac Dysautonomia in Drug-resistant Epilepsy
Epilepsy, Hypothalamus
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Fatih Kahraman, MD study director
Kutahya Health Sciences University Evliya Celebi Research and Training Hospital
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Death, Cardiac, run by Afyonkarahisar Health Sciences University at 2 sites in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
All cause mortality (time frame: In-hospital (up to two-weeks)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05296694, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Feb 2023.